A H Briggs

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. pmc New methods of analysing cost effectiveness
    Andrew H Briggs
    BMJ 335:622-3. 2007
  2. ncbi The death of cost-minimization analysis?
    A H Briggs
    Health Economics Research Centre, University of Oxford, UK
    Health Econ 10:179-84. 2001
  3. ncbi Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane
    A Briggs
    Health Economics Research Centre, Institute of Health Sciences, University of Oxford, Headington, UK
    Health Econ 7:723-40. 1998
  4. ncbi Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework
    Andrew H Briggs
    Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Headington, Oxford OX3 7LF, United Kingdom
    Med Decis Making 23:341-50. 2003
  5. ncbi Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease
    Andrew H Briggs
    Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Headington, United Kingdom
    Med Decis Making 22:290-308. 2002
  6. ncbi Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies
    Andrew H Briggs
    Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford OX3 7LF, United Kingdom
    Annu Rev Public Health 23:377-401. 2002
  7. ncbi Handling uncertainty in cost-effectiveness models
    A H Briggs
    Health Economics Research Centre, University of Oxford, England
    Pharmacoeconomics 17:479-500. 2000
  8. ncbi Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation
    A H Briggs
    Health Economics Research Centre, Oxford Institute of Health Sciences and Nuffield College, University of Oxford, U K
    Stat Med 18:3245-62. 1999
  9. ncbi An introduction to Markov modelling for economic evaluation
    A Briggs
    Health Economics Research Centre, Institute of Health Sciences, University of Oxford, England
    Pharmacoeconomics 13:397-409. 1998
  10. ncbi A Bayesian approach to stochastic cost-effectiveness analysis
    A H Briggs
    Health Economics Research Centre, University of Oxford, Headington, UK
    Health Econ 8:257-61. 1999

Detail Information

Publications25

  1. pmc New methods of analysing cost effectiveness
    Andrew H Briggs
    BMJ 335:622-3. 2007
  2. ncbi The death of cost-minimization analysis?
    A H Briggs
    Health Economics Research Centre, University of Oxford, UK
    Health Econ 10:179-84. 2001
    ..The first shows a situation where analysts might be tempted (inappropriately) to employ CMA rather than CEA. The second illustrates one of the rare circumstances in which CMA may be justified as a legitimate form of analysis...
  3. ncbi Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane
    A Briggs
    Health Economics Research Centre, Institute of Health Sciences, University of Oxford, Headington, UK
    Health Econ 7:723-40. 1998
    ..This approach is consistent with decision-making on the cost-effectiveness plane and with the cost-effectiveness acceptability curve approach to presenting uncertainty due to sampling variation in stochastic cost-effectiveness analyses...
  4. ncbi Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework
    Andrew H Briggs
    Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Headington, Oxford OX3 7LF, United Kingdom
    Med Decis Making 23:341-50. 2003
    ..Furthermore, they demonstrate that by adopting a Bayesian approach, the problem of observing zero counts for transitions of interest can be overcome...
  5. ncbi Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease
    Andrew H Briggs
    Health Economics Research Centre, University of Oxford, Institute of Health Sciences, Headington, United Kingdom
    Med Decis Making 22:290-308. 2002
    ..It is argued that probabilistic analyses should be encouraged because they have potential to quantify the strength of evidence in favor of particular treatment choices...
  6. ncbi Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies
    Andrew H Briggs
    Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford OX3 7LF, United Kingdom
    Annu Rev Public Health 23:377-401. 2002
    ..Finally, we outline some of the challenges for future research in this area-particularly in relation to the appropriate use of Bayesian methods and methods for analyzing costs that are typically skewed and often incomplete...
  7. ncbi Handling uncertainty in cost-effectiveness models
    A H Briggs
    Health Economics Research Centre, University of Oxford, England
    Pharmacoeconomics 17:479-500. 2000
    ..Such probabilistic analyses are related to parameter uncertainty. In addition, modelling uncertainty is likely to add a further layer of uncertainty to the results of particular analyses...
  8. ncbi Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation
    A H Briggs
    Health Economics Research Centre, Oxford Institute of Health Sciences and Nuffield College, University of Oxford, U K
    Stat Med 18:3245-62. 1999
    ..However, where it is suspected that the sampling distribution is skewed, normal approximation methods produce particularly poor results and should be avoided...
  9. ncbi An introduction to Markov modelling for economic evaluation
    A Briggs
    Health Economics Research Centre, Institute of Health Sciences, University of Oxford, England
    Pharmacoeconomics 13:397-409. 1998
    ..Analysts should be aware of the limitations of Markov models, particularly the Markovian assumption, although the adept modeller will often find ways around this problem...
  10. ncbi A Bayesian approach to stochastic cost-effectiveness analysis
    A H Briggs
    Health Economics Research Centre, University of Oxford, Headington, UK
    Health Econ 8:257-61. 1999
    ..Although it is argued that their interpretation as the probability that an intervention is cost-effective given the data requires a Bayesian interpretation, this should generate no misgivings for the frequentist...
  11. pmc Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK
    H E Campbell
    Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, Oxford OX3 7LF, UK
    Br J Cancer 103:776-86. 2010
    ....
  12. ncbi Statistical approaches to handling uncertainty in health economic evaluation
    Andrew H Briggs
    Health Economics Research Centre, Department of Public Health, University of Oxford, UK
    Eur J Gastroenterol Hepatol 16:551-61. 2004
    ..The second example is a secondary study of the management of gastro-oesophageal reflux disease symptoms which considered six potential strategies simultaneously...
  13. ncbi Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis
    Jeffrey S Hoch
    Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada
    Health Econ 11:415-30. 2002
    ....
  14. ncbi A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results
    Shelby D Reed
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, USA
    Med Decis Making 23:252-64. 2003
    ..Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations...
  15. ncbi Development of an economic model to assess the cost effectiveness of asthma management strategies
    Martin J Price
    Global Health Outcomes, GlaxoSmithKline Research and Development, Greenford, Middlesex, United Kingdom
    Pharmacoeconomics 20:183-94. 2002
    ..Because of the costs they incur, asthma exacerbations ('attacks') requiring intervention by a healthcare professional were a central consideration in the development of the model...
  16. ncbi Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models
    Andrea Manca
    Centre for Health Economics, University of York, UK
    Health Econ 14:471-85. 2005
    ....
  17. pmc Pharmacoeconomics in COPD: lessons for the future
    Helen J Starkie
    Public Health and Health Policy, University of Glasgow, Glasgow, UK
    Int J Chron Obstruct Pulmon Dis 3:71-88. 2008
    ....
  18. ncbi Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data
    Andrew H Briggs
    Public Health and Health Policy, University of Glasgow, Glasgow, UK
    Value Health 9:227-35. 2006
    ....
  19. ncbi Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization
    Yves M Gagnon
    Oxford Outcomes Ltd, 450 688 West Hastings Street, Vancouver, BC, Canada
    Respir Med 99:1534-45. 2005
    ....
  20. ncbi Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease
    Michael Spencer
    Global Health Outcomes, GlaxoSmithKline Research and Development, Greenford, Middlesex, UK
    Pharmacoeconomics 23:619-37. 2005
    ....
  21. ncbi Conducting economic evaluations alongside multinational clinical trials: toward a research consensus
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke University Medical Centre, Durham, NC, USA
    Am Heart J 149:434-43. 2005
    ..Delineation of the various approaches to multinational economic evaluation may assist researchers, peer reviewers, journal editors, and decision makers in evaluating the strengths and limitations of particular studies...
  22. ncbi Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection
    Yves M Gagnon
    Occam Research and Consulting Inc, Canada
    J Clin Gastroenterol 38:S179-86. 2004
    ..To estimate resource use and expected annual cost of care for subjects with chronic hepatitis B and resulting complications in Canada...
  23. ncbi Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data
    Andrew R Willan
    Program in Population Health Sciences, Hospital for Sick Children, and Department of Public Health Services, University of Toronto, ON, Canada
    Health Econ 13:461-75. 2004
    ..Furthermore, the method can exhibit efficiency gains over unrelated ordinary least squares regression...
  24. ncbi A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored
    Gordon Blackhouse
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Med Decis Making 22:173-7. 2002
    ..The authors address the joint problem of estimating ICER precision in the presence of censoring...
  25. ncbi A glossary of economic terms
    Naoki Chiba
    Eur J Gastroenterol Hepatol 16:563-5. 2004